Suppr超能文献

射频消融肾肿瘤后乳糜尿。

Chyluria after radiofrequency ablation of renal tumors.

机构信息

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.

出版信息

J Vasc Interv Radiol. 2011 Jul;22(7):924-7. doi: 10.1016/j.jvir.2011.02.014. Epub 2011 Apr 20.

Abstract

PURPOSE

To assess the incidence of chyluria after radiofrequency (RF) ablation of renal tumors and attempt to identify predictors of this phenomenon.

MATERIALS AND METHODS

Over a 3-year period, 62 consecutive patients with renal tumors were treated by percutaneous computed tomography (CT)-guided or laparoscopic RF ablation, of which 41 underwent at least three posttreatment CT studies and were evaluated in this study. Three radiologists reviewed the pretreatment and posttreatment CT images for the presence or absence of fat-fluid levels in the bladder, the location of the tumor, and the size of the postablation defect. A logistic regression model was used to assess whether ablation defect size or tumor location predicted chyluria.

RESULTS

Chyluria was detected at a mean time of 44.5 weeks in 17 (41%) of 41 patients with renal tumors treated by RF ablation. A pretreatment biopsy specimen showed renal cell carcinoma in 74%. Mean tumor size was 2.77 cm, and mean initial ablation size was 4.2 cm. Chyluria persisted in seven patients. Zone of ablation defect size and tumor location were not significant predictors of chyluria (P = .64 and P = .42). Mean follow-up was 77 weeks.

CONCLUSIONS

Chyluria is a common and asymptomatic finding in a significant proportion of patients undergoing RF ablation for renal tumors. Tumor location and zone of ablation defect size were not predictors of chyluria. The presence of a fat-fluid level should not be mistaken for an air-fluid level.

摘要

目的

评估射频(RF)消融肾肿瘤后乳糜尿的发生率,并尝试确定该现象的预测因素。

材料与方法

在 3 年期间,对 62 例连续接受经皮 CT 引导或腹腔镜 RF 消融治疗的肾肿瘤患者进行了治疗,其中 41 例至少进行了 3 次治疗后 CT 检查,并在本研究中进行了评估。3 名放射科医生回顾了术前和术后 CT 图像,以评估膀胱中是否存在脂肪-液体水平、肿瘤位置和消融后缺陷的大小。使用逻辑回归模型评估消融缺陷大小或肿瘤位置是否预测乳糜尿。

结果

41 例接受 RF 消融治疗的肾肿瘤患者中,有 17 例(41%)在平均时间为 44.5 周时检测到乳糜尿。术前活检标本显示肾细胞癌占 74%。平均肿瘤大小为 2.77cm,平均初始消融大小为 4.2cm。7 例患者的乳糜尿持续存在。消融缺陷区大小和肿瘤位置均不是乳糜尿的显著预测因素(P=0.64 和 P=0.42)。平均随访时间为 77 周。

结论

RF 消融治疗肾肿瘤后,乳糜尿是相当一部分患者的常见且无症状的发现。肿瘤位置和消融缺陷区大小不是乳糜尿的预测因素。存在脂肪-液体水平不应误诊为气-液体水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验